Biomaterials Risk Management BIORIMA H2020 grant

The Electrospinning Company is a partner in the EU funded H2020 Research and Innovation action BIORIMA (Biomaterial Risk Management). The project aims to develop an integrated risk management framework for nano-biomaterials used in advanced therapeutic medicinal products and medical devices. The BIORIMA risk management framework is a structure upon which the validated tools and methods… Read more »

BioBeat BioBusiness 2017

Ann Kramer, CEO of The Electrospinning Company is named as one of 50 female leaders in healthcare business in the UK in a report produced by BioBeat, 50 Movers and Shakers in BioBusiness 2017 , which emphasises how diversity of thinking is critical to the success of the sector in the UK. The 50 Movers and… Read more »

Stem cell culture in coated scaffolds

A simple 3-D culture system, made of electrospun polycaprolactone (PCL) fibers and coated with defined extracellular proteins that occur naturally in the stem cell niche, allowed dispersed attachment and culture of human pluripotent stem cells devoid of cell aggregation. A publication from The Royal Institute of Technology (KTH), Stockholm describes how PCL fiber scaffolds coated… Read more »

Stewart White appointed NED

The Electrospinning Company has strengthened its Board with the appointment of Dr Stewart White as non-executive director. Stewart was previously CEO of two life science AIM-quoted companies including Collagen Solutions Ltd., and is currently Chairman of Mikota Ltd and non-executive director with Taragenyx.  Stewart has international executive experience in commercial and product development, GMP manufacturing of… Read more »

KTP award for smart biomaterial development

The Electrospinning Company and the University of Nottingham have been awarded a Knowledge Transfer Partnership project to develop thermo-responsive scaffolds for 3D cell culture. The Electrospinning Company has a range of materials in development for use in 3D cell expansion in bioreactors, for example to increase the efficiency of the manufacture of stem cells for… Read more »

European project BONE

Eliminating the Need for Repeat Surgery. The Electrospinning Company is part of a European regional consortium led by Maastricht University (UM) which will spend the next four years developing innovative bone implants. These implants will become an alternative for repeat surgeries, prolonged medication use and donor tissue implementation following complex bone fractures. The BONE (Biofabrication… Read more »

Eye on the future

An interview in the Education Times of India with Professor MacNeil describing corneal damage and repair research. In an article published on 31 May 2017, Sheila MacNeil, professor of tissue engineering, department of materials science & engineering, Kroto Research Institute University of Sheffield, UK, speaks to Ruchi Chopda on the status of corneal damage treatment… Read more »

Muscle progenitor stem cells in 3D maintain character after expansion in Mimetix scaffolds

CD133+ progenitor stem cells were shown to maintain ‘stem-ness’ after expansion in Mimetix 3D cell culture. In a recent publication in the Journal of Biomaterials and Tissue Engineering, researchers at KTH in Sweden characterised the growth and differentiation of CD133+ stem cells in Mimetix 3D and in conventional 2D cell culture. CD133+ cells are myogenic progenitors… Read more »

Angel investment secured

The Electrospinning Company Announces £650,000 Investment to Fund Sales Growth and Increase Capacity Harwell, UK — 26 January 2017 — The Electrospinning Company, announces that it has secured a £650,000 investment to establish itself as the leading provider of clinical-grade electrospun biomaterials to the medical device industry. Funding has come from a network of UK… Read more »

3D tumour environment affects DNA damage

Cancer cells grown in 3D in Mimetix scaffolds or spheroid cultures responded to DNA damage  differently to those grown in conventional 2D culture. In “Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase. Joanne Wayne, Teresa Brooks, Andrew J. Massey. DOI: 10.18632/oncotarget.13119″ Vernalis researchers followed the regulation of… Read more »

Electrospinning Company strengthens the Board

The Electrospinning Company has appointed two new members to its Board of Directors to help develop its strategy and drive its growing business in the regenerative medical device sector. Drummond Paris and Nigel Edwards join Kate Ronayne (representing STFC Innovations), Malcolm Chapman (Angel investor) and Ann Kramer (CEO) as well as observer Mark White (Rainbow Seed… Read more »